Literature DB >> 15947628

Effect of lower urinary tract symptoms on the incidence of erectile dysfunction.

Rahman Shiri1, Jukka T Häkkinen, Matti Hakama, Heini Huhtala, Anssi Auvinen, Teuvo L J Tammela, Juha Koskimäki.   

Abstract

PURPOSE: We determined the effect of lower urinary tract symptoms (LUTS) on the incidence of erectile dysfunction (ED).
MATERIALS AND METHODS: The target population consisted of all men 50, 60 or 70 years old residing in Tampere area, Finland in 1994. Questionnaires were mailed to 3,143 men in 1994 and to 2,864 men 5 years later. The followup sample consisted of the 1,683 men who responded to baseline and followup questionnaires. We estimated the effect of LUTS and bother on the incidence of ED during the 5-year followup among the 1,126 men free from ED at baseline. ED was assessed by 2 questions on subject ability to achieve and maintain erection sufficient for intercourse and LUTS assessed by the Danish Prostatic Symptom Score. Logistic regression model was used in the multivariate analysis.
RESULTS: The incidence of ED increased with the presence and with the intensity of urinary symptoms and bother at baseline. Compared with men with LUTS score 0, the incidence of ED was 2.7 (95% CI 1.3-5.5) times higher among men with score 7 to 11, and 3.1 times with score 12 or more. The incidence of ED increased by 5% for each 1-point increment in LUTS score, while it increased by 12% and 11% for 1-point increment in cumulative symptom or bother score, respectively. Men with cumulative symptoms or bother score 4 or more were significantly 2.0 to 2.7 times at higher incidence of ED relative to those who were free from symptoms or bother at baseline. Only overflow incontinence (OR = 2.2) and incomplete emptying (OR = 1.8) independently increased the incidence of ED.
CONCLUSIONS: Lower urinary tract symptoms and bother independently increase the incidence of erectile dysfunction.

Entities:  

Mesh:

Year:  2005        PMID: 15947628     DOI: 10.1097/01.ju.0000162042.90554.64

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms.

Authors:  Gokhan Faydaci; Ugur Kuyumcuoglu; Bilal Eryildirim; Alper Aktas; Fatih Tarhan; Murat Tuncer
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

2.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

3.  The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Yunus Doğan; Fatih Uruç; Bekir Aras; Aytaç Şahin; Mithat Kıvrak; Ahmet Ürkmez; Numan Doğu Güner; Sabahattin Aydın
Journal:  Turk J Urol       Date:  2015-03

Review 4.  A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.

Authors:  Konstantinos Hatzimouratidis
Journal:  Ther Adv Urol       Date:  2014-08

5.  A prospective study of lower urinary tract symptoms and erectile dysfunction.

Authors:  Alison M Mondul; Eric B Rimm; Edward Giovannucci; Dale B Glasser; Elizabeth A Platz
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

6.  Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion.

Authors:  Jae Heon Kim; Ji Sung Shim; Hoon Choi; Du Geon Moon; Jeong Gu Lee; Je Jong Kim; Jae Hyun Bae; Jae Young Park
Journal:  BMC Urol       Date:  2015-08-29       Impact factor: 2.264

7.  Men's lower urinary tract symptoms are also mental and physical sufferings for their spouses.

Authors:  Sae Chul Kim; Shin Young Lee
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

Review 8.  The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.

Authors:  Stanisław Wroński
Journal:  Cent European J Urol       Date:  2014-08-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.